Dashenlin Pharm Grp Co Ltd
DaShenLin Pharmaceutical Group Co., Ltd. manufactures, distributes, and retails pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and antler tonic medicinal materials, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.
Dashenlin Pharm Grp Co Ltd (603233) - Net Assets
Latest net assets as of September 2025: CN¥8.49 Billion CNY
Based on the latest financial reports, Dashenlin Pharm Grp Co Ltd (603233) has net assets worth CN¥8.49 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥26.08 Billion) and total liabilities (CN¥17.59 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥8.49 Billion |
| % of Total Assets | 32.55% |
| Annual Growth Rate | 29.06% |
| 5-Year Change | 46.03% |
| 10-Year Change | 696.94% |
| Growth Volatility | 32.03 |
Dashenlin Pharm Grp Co Ltd - Net Assets Trend (2012–2024)
This chart illustrates how Dashenlin Pharm Grp Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Dashenlin Pharm Grp Co Ltd (2012–2024)
The table below shows the annual net assets of Dashenlin Pharm Grp Co Ltd from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥8.14 Billion | +2.59% |
| 2023-12-31 | CN¥7.93 Billion | +15.57% |
| 2022-12-31 | CN¥6.86 Billion | +15.64% |
| 2021-12-31 | CN¥5.94 Billion | +6.51% |
| 2020-12-31 | CN¥5.57 Billion | +28.65% |
| 2019-12-31 | CN¥4.33 Billion | +40.33% |
| 2018-12-31 | CN¥3.09 Billion | +10.13% |
| 2017-12-31 | CN¥2.80 Billion | +108.83% |
| 2016-12-31 | CN¥1.34 Billion | +31.42% |
| 2015-12-31 | CN¥1.02 Billion | +77.65% |
| 2014-12-31 | CN¥574.85 Million | -2.56% |
| 2013-12-31 | CN¥589.93 Million | +54.79% |
| 2012-12-31 | CN¥381.11 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Dashenlin Pharm Grp Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2738.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥3.84 Billion | 55.62% |
| Common Stock | CN¥1.14 Billion | 16.51% |
| Other Components | CN¥1.92 Billion | 27.87% |
| Total Equity | CN¥6.90 Billion | 100.00% |
Dashenlin Pharm Grp Co Ltd Competitors by Market Cap
The table below lists competitors of Dashenlin Pharm Grp Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Takeuchi Mfg. Co., Ltd.
OTCGREY:TKUGF
|
$1.01 Billion |
|
Xinxiang Richful Lube Additive Co. Ltd
SHE:300910
|
$1.01 Billion |
|
AQ Group AB (publ)
F:7AQ0
|
$1.01 Billion |
|
Lufax Holding Ltd
NYSE:LU
|
$1.01 Billion |
|
3M India Limited
NSE:3MINDIA
|
$1.01 Billion |
|
Ningbo Xusheng Auto Technology Co Ltd
SHG:603305
|
$1.01 Billion |
|
Yinson Holdings Bhd
KLSE:7293
|
$1.01 Billion |
|
Ducgiang Chemicals & Detergent Powder Joint Co
VN:DGC
|
$1.01 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dashenlin Pharm Grp Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,823,853,093 to 6,897,244,933, a change of 73,391,840 (1.1%).
- Net income of 914,754,952 contributed positively to equity growth.
- Dividend payments of 753,211,785 reduced retained earnings.
- Share repurchases of 101,797,463 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥914.75 Million | +13.26% |
| Dividends Paid | CN¥753.21 Million | -10.92% |
| Share Repurchases | CN¥101.80 Million | -1.48% |
| Other Changes | CN¥13.65 Million | +0.2% |
| Total Change | CN¥- | 1.08% |
Book Value vs Market Value Analysis
This analysis compares Dashenlin Pharm Grp Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.12x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 29.41x to 3.12x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.65 | CN¥19.07 | x |
| 2013-12-31 | CN¥0.72 | CN¥19.07 | x |
| 2014-12-31 | CN¥0.68 | CN¥19.07 | x |
| 2015-12-31 | CN¥1.18 | CN¥19.07 | x |
| 2016-12-31 | CN¥1.35 | CN¥19.07 | x |
| 2017-12-31 | CN¥2.71 | CN¥19.07 | x |
| 2018-12-31 | CN¥2.81 | CN¥19.07 | x |
| 2019-12-31 | CN¥3.20 | CN¥19.07 | x |
| 2020-12-31 | CN¥4.75 | CN¥19.07 | x |
| 2021-12-31 | CN¥4.82 | CN¥19.07 | x |
| 2022-12-31 | CN¥5.47 | CN¥19.07 | x |
| 2023-12-31 | CN¥6.03 | CN¥19.07 | x |
| 2024-12-31 | CN¥6.11 | CN¥19.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dashenlin Pharm Grp Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.26%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.45%
- • Asset Turnover: 1.00x
- • Equity Multiplier: 3.83x
- Recent ROE (13.26%) is below the historical average (26.15%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 45.45% | 4.59% | 3.26x | 3.04x | CN¥116.36 Million |
| 2013 | 37.55% | 5.33% | 2.21x | 3.20x | CN¥144.82 Million |
| 2014 | 53.08% | 5.84% | 1.92x | 4.73x | CN¥215.49 Million |
| 2015 | 38.72% | 7.51% | 1.98x | 2.60x | CN¥293.32 Million |
| 2016 | 32.65% | 6.86% | 1.75x | 2.72x | CN¥298.45 Million |
| 2017 | 17.25% | 6.40% | 1.27x | 2.12x | CN¥199.68 Million |
| 2018 | 17.50% | 6.00% | 1.36x | 2.15x | CN¥227.82 Million |
| 2019 | 16.57% | 6.31% | 1.28x | 2.05x | CN¥278.67 Million |
| 2020 | 19.73% | 7.28% | 1.18x | 2.29x | CN¥523.70 Million |
| 2021 | 14.44% | 4.72% | 0.97x | 3.16x | CN¥243.37 Million |
| 2022 | 16.67% | 4.87% | 1.02x | 3.36x | CN¥414.54 Million |
| 2023 | 17.09% | 4.76% | 1.02x | 3.54x | CN¥484.11 Million |
| 2024 | 13.26% | 3.45% | 1.00x | 3.83x | CN¥225.03 Million |
Industry Comparison
This section compares Dashenlin Pharm Grp Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dashenlin Pharm Grp Co Ltd (603233) | CN¥8.49 Billion | 45.45% | 2.07x | $1.01 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |